PILOT OF BUTHIONINE SULFOXIMINE WITH MELPHALAN IN NEUROBLASTOMA

丁硫氨酸亚磺酰亚胺联合美法仑治疗神经母细胞瘤的试验

• 批准号: 6113655
• 负责人: CLARK ANDERSON
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113655
• 关键词: buthionine sulfoximine; child (0-11); clinical research; drug screening /evaluation; glutathione; human subject; lymphocyte; melphalan; neoplasm /cancer chemotherapy; neuroblastoma; pediatric neoplasm /cancer; pediatric pharmacology; pharmacokinetics

Treatment failure in neuroblastoma likely involves acquired alkylator resistance and the anti-tumor effect of alkylating agents may be increased by depletion of glutathione (GSH) with the drug buthionine sulfoximine (BSO). This study will evaluate the pharmacokinetics and clinical toxicities of the combination of (BS0) and melphalan in pediatric patients with neuroblastoma. An additional goal of this study is to document GSH depletion in peripheral blood lymphocytes, normal marrow and neuroblastoma cells found in the bone marrow.

神经母细胞瘤的治疗失败可能涉及获得性烷化剂耐药性，并且烷化剂的抗肿瘤作用可能通过药物丁硫氨酸亚砜亚胺（BSO）耗尽谷胱甘肽（GSH）而增加。本研究将评价（BS 0）和美法仑联合治疗儿童神经母细胞瘤患者的药代动力学和临床毒性。本研究的另一个目的是记录外周血淋巴细胞、正常骨髓和骨髓中发现的神经母细胞瘤细胞中的GSH耗竭。